IL306088A - Vaccine formulations against coronavirus - Google Patents

Vaccine formulations against coronavirus

Info

Publication number
IL306088A
IL306088A IL306088A IL30608823A IL306088A IL 306088 A IL306088 A IL 306088A IL 306088 A IL306088 A IL 306088A IL 30608823 A IL30608823 A IL 30608823A IL 306088 A IL306088 A IL 306088A
Authority
IL
Israel
Prior art keywords
vaccine formulations
coronavirus vaccine
coronavirus
formulations
vaccine
Prior art date
Application number
IL306088A
Other languages
English (en)
Hebrew (he)
Inventor
Gale Smith
Michael J Massare
Jing-Hui Tian
Original Assignee
Novavax Inc
Gale Smith
Michael J Massare
Tian jing hui
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Novavax Inc, Gale Smith, Michael J Massare, Tian jing hui filed Critical Novavax Inc
Publication of IL306088A publication Critical patent/IL306088A/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/215—Coronaviridae, e.g. avian infectious bronchitis virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/39—Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55577—Saponins; Quil A; QS21; ISCOMS
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/57—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/57—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2
    • A61K2039/575—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2 humoral response
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011—Details
    • C12N2770/20011—Coronaviridae
    • C12N2770/20022—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011—Details
    • C12N2770/20011—Coronaviridae
    • C12N2770/20034—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011—Details
    • C12N2770/20011—Coronaviridae
    • C12N2770/20071—Demonstrated in vivo effect

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Virology (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Molecular Biology (AREA)
  • Communicable Diseases (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biophysics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Genetics & Genomics (AREA)
  • Oncology (AREA)
  • Pulmonology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicinal Preparation (AREA)
  • Peptides Or Proteins (AREA)
IL306088A 2021-03-22 2022-03-18 Vaccine formulations against coronavirus IL306088A (en)

Applications Claiming Priority (9)

Application Number Priority Date Filing Date Title
US202163164487P 2021-03-22 2021-03-22
US202163176825P 2021-04-19 2021-04-19
US202163177059P 2021-04-20 2021-04-20
US202163195986P 2021-06-02 2021-06-02
US202163280395P 2021-11-17 2021-11-17
US202163290439P 2021-12-16 2021-12-16
US202163292196P 2021-12-21 2021-12-21
US202163293468P 2021-12-23 2021-12-23
PCT/US2022/020974 WO2022203963A1 (en) 2021-03-22 2022-03-18 Coronavirus vaccine formulations

Publications (1)

Publication Number Publication Date
IL306088A true IL306088A (en) 2023-11-01

Family

ID=83396030

Family Applications (1)

Application Number Title Priority Date Filing Date
IL306088A IL306088A (en) 2021-03-22 2022-03-18 Vaccine formulations against coronavirus

Country Status (11)

Country Link
US (1) US20220332765A1 (cg-RX-API-DMAC7.html)
EP (1) EP4313143A4 (cg-RX-API-DMAC7.html)
JP (1) JP2024511412A (cg-RX-API-DMAC7.html)
KR (1) KR20230160349A (cg-RX-API-DMAC7.html)
AU (1) AU2022245141A1 (cg-RX-API-DMAC7.html)
BR (1) BR112023019301A2 (cg-RX-API-DMAC7.html)
CA (1) CA3213221A1 (cg-RX-API-DMAC7.html)
IL (1) IL306088A (cg-RX-API-DMAC7.html)
MX (1) MX2023011163A (cg-RX-API-DMAC7.html)
TW (1) TW202304955A (cg-RX-API-DMAC7.html)
WO (1) WO2022203963A1 (cg-RX-API-DMAC7.html)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN120227451A (zh) * 2018-03-19 2025-07-01 诺瓦瓦克斯股份有限公司 多价流感纳米颗粒疫苗
US10953089B1 (en) 2020-01-27 2021-03-23 Novavax, Inc. Coronavirus vaccine formulations
AU2021214064A1 (en) 2020-01-27 2022-08-18 Novavax, Inc. Coronavirus vaccine formulations
JP2025511756A (ja) 2022-04-08 2025-04-16 フラッグシップ パイオニアリング イノベーションズ セブン,エルエルシー ワクチン及び関連する方法
EP4648794A2 (en) 2023-01-09 2025-11-19 Flagship Pioneering Innovations VII, LLC Vaccines and related methods
WO2024258829A1 (en) 2023-06-12 2024-12-19 Flagship Pioneering Innovations Vii, Llc Sars-cov-2 vaccine compositions and related methods
WO2025054236A2 (en) 2023-09-06 2025-03-13 Flagship Pioneering Innovations Vii, Llc Sars-cov-2 vaccine compositions and related methods
IL327905A (en) * 2023-10-25 2026-06-01 Novavax Inc Saponin-based adjuvants and methods of characterizing same

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2968510B1 (en) * 2013-03-14 2019-10-09 President and Fellows of Harvard College Nanoparticle-based compositions
US10953089B1 (en) * 2020-01-27 2021-03-23 Novavax, Inc. Coronavirus vaccine formulations
US20210228707A1 (en) * 2020-01-28 2021-07-29 Modernatx, Inc. Coronavirus rna vaccines
TW202204380A (zh) * 2020-01-31 2022-02-01 美商詹森藥物公司 用於預防及治療冠狀病毒感染之組合物及方法-sars-cov-2疫苗
US10906944B2 (en) * 2020-06-29 2021-02-02 The Scripps Research Institute Stabilized coronavirus spike (S) protein immunogens and related vaccines

Also Published As

Publication number Publication date
EP4313143A4 (en) 2025-06-18
TW202304955A (zh) 2023-02-01
AU2022245141A1 (en) 2023-10-05
US20220332765A1 (en) 2022-10-20
AU2022245141A9 (en) 2024-02-22
EP4313143A1 (en) 2024-02-07
KR20230160349A (ko) 2023-11-23
JP2024511412A (ja) 2024-03-13
CA3213221A1 (en) 2022-09-29
BR112023019301A2 (pt) 2023-12-05
MX2023011163A (es) 2024-02-27
WO2022203963A1 (en) 2022-09-29

Similar Documents

Publication Publication Date Title
GB202212336D0 (en) Coronavirus vaccine formulations
GB2594365B (en) Coronavirus vaccine
IL314906B2 (en) Coronavirus vaccine
GB202004974D0 (en) Coronavirus vaccine
ZA202210641B (en) Coronavirus vaccine
GB202217951D0 (en) Coronavirus vaccine
IL297070A (en) Vaccine against the corona virus
EP4313143A4 (en) Coronavirus vaccine formulations
GB2620028B8 (en) Coronavirus vaccine
GB202207281D0 (en) Vaccine
HK40117626A (en) Coronavirus vaccine formulations
HK40105934A (en) Coronavirus vaccine formulations
HK40075990A (en) Coronavirus vaccine formulations
GB202016172D0 (en) Coronavirus vaccine
GB202114318D0 (en) Coronavirus Vaccines
GB202103214D0 (en) Coronavirus vaccines
GB202101824D0 (en) Coronavirus vaccines
GB202015775D0 (en) Coronavirus vaccines
GB202318080D0 (en) Coronavirus vaccines
GB202315819D0 (en) Coronavirus vaccines
GB202315824D0 (en) Coronavirus vaccines
GB202312413D0 (en) Coronavirus vaccines
GB202312403D0 (en) Coronavirus vaccines
GB202305092D0 (en) Coronavirus vaccines
GB202303150D0 (en) Coronavirus vaccines